Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far
This article was originally published in Scrip
Executive Summary
One should not rule out Pfizer Inc. selling off more biosimilars than required under antitrust rules in its acquisition of Hospira Inc. All five biosimilars in Pfizer's clinical pipeline overlap with those in Hospira's, but even though only infliximab is required to be divested, the others could also be sold off to reach cost-saving targets.
You may also be interested in...
Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.
Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.
FTC Commissioner Recusal Decisions Should Be Public, US Chamber Of Commerce Says
Chamber files petition to have FTC amend its disqualification rules to have commissioners explain their rejection of recusal requests. FTC is seeking public comments on the petition.